VIENNA, Austria, September 27th, 2021 — Delta4, a digital drug discovery company focusing on the identification of new indications for […]
News
Delta4 expands Team and tackles new indications
Following our Financing in March 2021 and our move into new premises in July 2021 we are continuing to expand […]
Office News – July ’21
We are excited to announce that Delta4 has moved into a new office in the 8th district, close to the city […]
Alfred Steininger to Join Delta4 as CFO
We are very pleased to introduce Alfred Steininger as our new Chief Financial Officer, starting in mid-July 2021. Alfred brings […]
Press Release – April ’21
Delta4 Announces Closing of Multi-million Series A Financing Round Company to Expand Focus Beyond Renal Diseases and COVID-19 Compounds Identified […]
FSGS and COVID-19 programs ready for Phase II studies
We are proud to announce further progress in our current drug discovery and development programs. In late 2020, Delta4 filed […]
Delta4 files four patent applications in FSGS and COVID-19
We are very pleased to announce that Delta4 has filed four patent applications for compounds and combinations of compounds in […]
BIO-Europe 2020 Digital – Partnering Event
Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to […]
Sachs 20th Annual Biotech in Europe Forum
The 20th Annual Biotech in Europe (BEF) Forum is recognised as the leading international Stage for those interested in investing […]
Global Orphan Drug Conference
With over 1,500 attendees from 50+ countries the 2020 edition of World Orphan Drug Congress USA was held online August […]